A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas
The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.
Sarcoma, Soft Tissue
DRUG: Eribulin mesylate
Number of Adverse Events (AEs) and Adverse Drug Reactions (ADRs), up to 2 years
Survival Rate at Year 2, up to 2 years
The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.